Peter G. Steinherz, MD
Pediatric Hematologic Oncologist
Pediatric Oncology; Leukemias; Lymphomas: Hodgkin and non-Hodgkin Lymphoma; Wilms' Tumor; Developmental Chemotherapy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Steinherz accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Albert Einstein College of Medicine
Pediatrics - New York Hospital/Cornell Medical Center
Pediatric Hematology/Oncology - Cornell University Medical College
Pediatrics; Pediatric Hematology-Oncology
I am a pediatric hematologic oncologist on the MSK Kids team who cares for infants, children, and young adults with cancer. In my research, I study the biology of leukemia, lymphoma, and Wilms’ tumor, as well as develop therapies that improve the long-term survival of people with these cancers.
For more than 40 years here at Memorial Sloan Kettering, I have directed the treatment of children and adolescents with leukemia. During this time, my colleagues and I developed new treatment protocols for leukemia, including the New York I and New York II protocols. These are now used as the standard of care all over the world. These treatment regimens have improved the survival of people with acute lymphoblastic leukemia (ALL), the most common cancer in children, from 50 percent in the 1970s to more than 80 percent for high-risk patients and more than 90 percent for standard-risk patients today.
We have also studied new drugs and new combinations of drugs in people with leukemia that has become resistant to standard therapies, and we have improved the survival of these children and young adults. We are continuing our research to develop more-effective therapies for pediatric leukemia that returns after initial treatment.
I have been a member of the Leukemia Strategy Group of the Children’s Oncology Group for more than 20 years. I have chaired or co-chaired 11 large national and international studies for the group and have been a committee member of many other investigations. These research studies evaluate different treatments, including investigational therapies, for young patients with leukemia, lymphoma, or other cancers. I am a member of the National Comprehensive Cancer Network committee that develops national guidelines for the treatment of children with ALL. I recently stepped down from my role as a principal investigator of the Children’s Oncology Group, a position that I was privileged to have since the group’s inception.
At Memorial Sloan Kettering, we have state-of-the-art therapies for the cancers and cancer-related problems that are most frequently seen in young patients. But we also care for children with unusual tumors or cancer-related illnesses. We treat each child or young adult as an individual. When necessary, we create tailor-made therapies to meet their unique needs. Instead of trying to fit a patient to a therapy, we make the therapy fit the patient. We do everything we can to help our patients get better.
MSK Kids was also among the first to recognize the stress that cancer and its treatment can have on children and their families. We have observed the long-term physical and emotional effects of cancer therapy in young patients. For many years, we have taken steps to minimize these effects. There is nothing more rewarding than seeing one of my patients finish therapy and return to their normal activities, with no negative memories of the treatment process. I love to go to their happy life events, such as bar mitzvahs and weddings, and to watch their own children grow.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Co-Investigated by Dr. Steinherz
- ALTE03N1: Key Adverse Events Following Childhood Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Boulad F, Steinherz P, Reyes B, et al. Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single-institution study. J Clin Oncol 1999; 17 :197
Gaynon PS, Bleyer WA, Steinherz PG, Finklestein J, Littman P, Miller DR, Reaman G, Sather H. Modified BFM therapy for children with previously untreated acute lymphoblastic. Am. J Ped Hemat Oncol 1988; 10 :42-50
Steinherz PG, Meyers P, Wollner N, Redner A, Tan C. Reinduction therapy for advanced or. Cancer 1989; 63:1472-1476
Steinherz P, Gaynon P, Haimi J, Meyers P, Redner A, Steinherz L, Andreeff M, Hammond D. Improved survival of children with high-risk acute lymphoblastic leukemia: Report from the Childrens. NewYork: Wiley-Liss 1989; 147-156
Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather H. Day-7 marrow response and outcome for children with acute lymphoblastic. Med Ped Oncol 1990; 18 :273-279
Steinherz PG, Siegel SE, Bleyer A, Kersey J, Chard R, Coccia P, Leikin S, Lukens J, Neerhout R, Nesbit M, Miller DR, Reaman G, Sather H, Hammond D. Lymphomatous presentation of childhood acute lymphoblastic leukemia, a subgroup at high risk of early treatment failure.. Cancer 1991; 68 :751-758
Steinherz PG, Gaynon P, Trigg M, Sather H, Bleyer AW. Cytoreduction and prognosis in acute lymphoblastic leukemia—the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996; 14 :2403-24-6
Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 1996; 88 :4288-4295
Uckun FM, Reaman G, Steinherz PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after. Leukemia Lymphoma 1998; 24 :57-70
Pui C-H, Steinherz P, Kernan N, Wharam M, Sallan S, Zipf T, Sanders J, O’Reilly R. National Comprehensive Cancer Network, pediatric acute lymphoblastic leukemia practice guidelines. Oncology 1996; 10 :1787-1794
Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children’s Cancer Group. Cancer 1998; 82 :600-612
Uckun FM, Reaman G, Steinherz PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after. Leukemia Lymphoma 1998; 83 :2030-2039
Steinherz PG. Acute lymphoblastic leukemia – Children In: J.R. Bertino ed. Encyclopedia of Cancer. Academic Press 2002.
Steinherz P. Wilms’ tumor. In: Finberg L, ed. Sanders Manual of Pediatric Practice. Philadelphia. W.B. Sanders 2002.
Visit PubMed for a full listing of Dr. Steinherz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Peter G. Steinherz discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.